Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320923 | 0.87 | KDM4E (0.57) | KDM4EALDH1A1GLAHSD11B1KMT2A | |
| SCHEMBL13949550 | 0.86 | NPC1 (0.46) | KDM4EALDH1A1GLAHSD11B1KMT2A | |
| SCHEMBL3321977 | 0.78 | HSD11B1 (0.69) | KDM4EALDH1A1GLAHSD11B1KMT2A | |
| SCHEMBL3322037 | 0.75 | HSD11B1 (0.69) | KDM4EALDH1A1GLAHSD11B1NPC1 | |
| SCHEMBL13590484 | 0.75 | CNR2 (0.57) | ALDH1A1KMT2AEPHX2FAAHMEN1 | |
| SCHEMBL13949886 | 0.74 | KDM4E (0.43) | KDM4EALDH1A1GLAHSD11B1KMT2A | |
| SCHEMBL3323180 | 0.72 | HSD11B1 (0.56) | KDM4EALDH1A1HSD11B1KMT2ACYP3A4 | |
| SCHEMBL13064065 | 0.72 | KMT2A (0.47) | KDM4EALDH1A1KMT2AEPHX2FAAH | |
| SCHEMBL14644904 | 0.71 | EPHX2 (0.57) | ALDH1A1KMT2AEPHX2MEN1MAPK1 | |
| SCHEMBL15009750 | 0.71 | KDM4E (0.59) | KDM4EALDH1A1GLAHSD11B1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| EP-1861384-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Sterix Limited (GB) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006100502-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | STERIX LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | KDM4E 1839/4885ALDH1A1 437/4885GLA 3321/4885 |
| US-20100120789-A1 | Compound | NR0B2, NR0B1, NR4A1 | KDM4E 1594/4885ALDH1A1 3143/4885GLA 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.